Stryker reported extraordinary financial growth with revenue increasing 314.7% to $25.1B and net income surging 277.9% to $3.2B, indicating a transformational year likely driven by major acquisitions or accounting changes.
The magnitude of these increases far exceeds organic growth expectations and suggests either significant M&A activity, a major business restructuring, or potential accounting restatements that fundamentally altered the company's financial profile. The increase in outstanding shares from 381.6M to 382.7M and debt rising 73% to $1.8B supports the M&A hypothesis, while the company's competitive positioning disclosure in medical devices provides context for this expansion strategy.
Stryker delivered exceptional financial performance with revenue quadrupling to $25.1B and net income nearly tripling to $3.2B, while gross profit margins expanded dramatically from 64% to 64% despite the scale increase. The balance sheet shows measured expansion with assets growing 11.3% to $47.8B and equity increasing 17.7% to $11.7B, while debt increased 73% but remains manageable at $1.8B. Operating cash flow growth of 18.9% to $5.0B demonstrates strong cash generation capabilities that support the company's growth investments, though the disconnect between revenue growth and cash flow growth warrants further investigation.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Strong top-line growth of 314.7% — accelerating demand or successful expansion into new markets.
Net income grew 277.9% — bottom-line growth signals improving overall business health.
Debt increased 73% — substantial leverage increase; assess whether deployed for growth or covering losses.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Operating cash flow grew 18.9% — strong conversion of earnings to cash, healthy business fundamentals.
Equity base grew 17.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Liabilities increased 13.8% — monitor debt-to-equity ratio and interest coverage.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Asset base grew 11.3% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →